Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026986 (
myelodysplastic syndrome
)
14,926
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To find the underlying causes of primary
myelodysplastic syndrome
(
MDS
), the gene expression profiling of both CD34+ cells and bone marrow mononuclear cells from
MDS
patients was performed using oligonucleotide microarray and cDNA microarrays, respectively. Several candidate genes which were differentially expressed in
MDS
patients versus normal controls were selected and confirmed in expanding samples by quantitative real-time reverse transcription-polymerase chain reaction after clustering and bioinformatics analysis. one of these genes,
RAP1GAP
, was found to be expressed at a significantly higher level in patients with
MDS
in comparison with those suffering from other hematopoietic diseases including leukemia (P < 0.01). We propose that over-expression of
RAP1GAP
gene may play a role in the pathogenesis of
MDS
.
...
PMID:Expression of Rap1GAP in human myeloid disease following microarray selection. 1855 4
Previous study on the gene expression profile of human
MDS
by using microarray discovered that transcription of
RAP1GAP
was up-regulated, which was confirmed by quantitative RT-PCR in expanding cohort of
MDS
patients. This study was pourposed to investigate the expression of
RAP1GAP
in human
MDS
and its clinical relevance. The expression of
RAP1GAP
in bone marrow cells of 19
MDS
patients was detected by flow cytometry and was compared with that in patients with non-malignant blood diseases and acute leukemias, meanwhile the relevance between expression level of
RAP1GAP
and hemoglobin, leukocytes, platelets, blasts percentage in bone marrow cells and IPSS score was analyzed. The results indicated that the expression level of RAP1GAp in
MDS
patients significantly increased as compared with patients with non-malignant blood diseases or AML (8.42 +/- 8.37% vs 2.97 +/- 4.75% or 2.26 +/- 4.24%). Among
MDS
patients, the expression level of
RAP1GAP
in
MDS
-RA was significantly higher than that in
MDS
-RAEB (11.64 +/- 9.07% vs 4.37 +/- 4.65%). However, no definitive correlation of expression level with above-mentioned clinical parameters was found in detected patients with DMS. In conclusion, the expression of
RAP1GAP
in
MDS
patients obviously increases, the relationship between expression level of
RAP1GAP
and laboratory hematological parameter and IPSS score does not be confirmed. The role played by
RAP1GAP
expression in the pathogenesis of
MDS
and its clinical significance during progression of
MDS
towards AML deserves further studies.
...
PMID:Protein RAP1GAP in human myelodysplastic syndrome detected by flow cytometry and its clinical relevance. 1954 74
